After Some Hostilities, Glaxo Agrees To Buy HGS For $3.6B |
| July 17, 2012 | July 2012 Bond Updates |
|
Ending the tug-of-war between the two companies, the boards of GlaxoSmithKline (GSK) and Human Genome Sciences (HGS) agreed on a transaction price. On Monday, HGS announced it agreed to a $14.25 per share offer by GSK, valuing the company at about $3.6 billion; after an initial refusal by HGS, GSK pursued a hostile takeover of the company, but eventually upped their offer and closed the deal on friendly terms. |
| View more at: http://www.forbes.com/sites/afontevecchia/2012/07/16/after-some-hostilities-glaxo-agrees-to-buy-hgs-for-3-6b/ |
| Related News |